David Woolf

Has grant

Honorary Senior Lecturer

University of Manchester

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

David Woolf is an Honorary Senior Lecturer at the University of Manchester, United Kingdom. His research primarily focuses on the integration of targeted therapies and radiotherapy for lung and prostate cancers, as evidenced by his recent publications. He has explored various aspects of patient-reported outcomes and the feasibility of new approaches in cancer care.

Recent Grants

Grant: Open

ThOracic Umbrella RadIotherapy STudy in stage IV NSCLC - TOURIST

Open Date: 2023-04-01

Close Date: 2028-09-30

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (4)

Meritxell Molla

Associate Professor

University of Barcelona

SPAIN

View details

Hitesh Mistry

The University of Manchester

UNITED KINGDOM

View details

Adrian Cook

University College London

UNITED KINGDOM

View details

Cynthia Eccles

Honorary Senior Lecturer

The University of Manchester

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

David Woolf

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (10)

Emerging Role of Targeted Therapies Combined With Radiotherapy in Inoperable Stages I to III NSCLC: A Review From the IASLC ART Subcommittee

Integrating Electronic Patient-Reported Outcome Measures (ePROMs) into Personalised Follow-up for Patients after Radiotherapy. A Feasibility Study

Professional-patient discrepancies in assessing lung cancer radiotherapy symptoms: An international multicentre study

A study demonstrating users’ preference for the adapted-REQUITE patient-reported outcome questionnaire over PRO-CTCAE in patients with lung cancer

Does the presence of Magtrace preclude adaptive breast radiotherapy on an MR-Linac?

Palliative Radiotherapy Practice in Lung Cancer: Time to Advance?

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial

Exploring the Advantages and Challenges of MR-Guided Radiotherapy in Non–Small-Cell Lung Cancer: Who are the Optimal Candidates?

Service Evaluation of MyChristie-MyHealth, an Electronic Patient-Reported Outcome Measure Integrated into Clinical Cancer Care

Collaborators (4)

Meritxell Molla

Hitesh Mistry

Adrian Cook

Cynthia Eccles

Make your next move.